Exelixis sees three Farallon nominees elected to board

• Farallon Capital Management's three nominees for Exelixis' (NASDAQ:EXEL) board have been elected to the biotech's board.
• The new directors are Tom Heyman, Dave Johnson, and Bob Oliver.
• Farallon owns a ~7.2% stake in Exelixis (EXEL).
• "We expect the remaining incumbent directors to heed the clear message of this election and recognize that Exelixis must embrace change to achieve its full potential for patients and shareholders," Farallon said in a statement.

More on Farallon and Exelixis

• Exelixis board member resigns; Farallon gets third board seat in victory

• Exelixis holder Farallon files definitive materials in proxy battle